Comparison of outcomes between neoadjuvant imatinib and upfront surgery in patients with localized rectal GIST: An inverse probability of treatment weighting analysis

Author(s):  
Jia‐Yu Ling ◽  
Miao‐Miao Ding ◽  
Zi‐Feng Yang ◽  
Yan‐Dong Zhao ◽  
Xiao‐Yu Xie ◽  
...  

SAGE Open ◽  
2021 ◽  
Vol 11 (1) ◽  
pp. 215824402097999
Author(s):  
Aloyce R. Kaliba ◽  
Anne G. Gongwe ◽  
Kizito Mazvimavi ◽  
Ashagre Yigletu

In this study, we use double-robust estimators (i.e., inverse probability weighting and inverse probability weighting with regression adjustment) to quantify the effect of adopting climate-adaptive improved sorghum varieties on household and women dietary diversity scores in Tanzania. The two indicators, respectively, measure access to broader food groups and micronutrient and macronutrient availability among children and women of reproductive age. The selection of sample households was through a multistage sampling technique, and the population was all households in the sorghum-producing regions of Central, Northern, and Northwestern Tanzania. Before data collection, enumerators took part in a 1-week training workshop and later collected data from 822 respondents using a structured questionnaire. The main results from the study show that the adoption of improved sorghum seeds has a positive effect on both household and women dietary diversity scores. Access to quality food groups improves nutritional status, food security adequacy, and general welfare of small-scale farmers in developing countries. Agricultural projects that enhance access to improved seeds are, therefore, likely to generate a positive and sustainable effect on food security and poverty alleviation in sorghum-producing regions of Tanzania.



2021 ◽  
Vol 40 (9) ◽  
pp. 2101-2112
Author(s):  
Mitchell M. Conover ◽  
Kenneth J. Rothman ◽  
Til Stürmer ◽  
Alan R. Ellis ◽  
Charles Poole ◽  
...  


2021 ◽  
Vol 14 (4) ◽  
pp. e240872
Author(s):  
Dhilip Andrew ◽  
Karthik Shyam ◽  
Jovis Johny ◽  
Rini Jose
Keyword(s):  


2020 ◽  
Vol 22 (11) ◽  
pp. 1792-1792
Author(s):  
M. Laurini Zanola ◽  
J. Wright ◽  
M. Viola Malet ◽  
P. Rodríguez Goñi ◽  
J. Monson ◽  
...  


Biometrics ◽  
2021 ◽  
Author(s):  
Sujatro Chakladar ◽  
Samuel P. Rosin ◽  
Michael G. Hudgens ◽  
M. Elizabeth Halloran ◽  
John D. Clemens ◽  
...  


2021 ◽  
pp. 174749302110294
Author(s):  
Peter Nielsen ◽  
Mette Soegaard ◽  
Martin Jensen ◽  
Anne G Ording ◽  
Gregory Lip

Background and purpose: The effectiveness and safety of edoxaban 60 mg and 30 mg for stroke prevention compared with warfarin in patients with atrial fibrillation (AF) has not been well-described in a nationwide cohort of Caucasian patients treated in standard clinical practice. Methods: We used Danish nationwide registries to identify patients with AF during June 2016 and November 2018 who were treated with edoxaban or warfarin and computed rates per 100 person-years of thromboembolic, all-cause mortality, and bleeding events using an inverse probability of treatment weighting approach to account for baseline confounding. We used weighted pooled logistic regression to compute hazard ratios (HRs) with 95% confidence intervals (CIs) comparing events between edoxaban 60 mg and warfarin users; edoxaban 30 mg was not included in formal comparisons. Results: We identified 6451 AF patients, mean age was 72 years and 40% were females. A total of 1772 patients were treated with edoxaban 60 mg, 537 with edoxaban 30 mg, and 4142 with warfarin. The median CHA2DS2-VASc score was similar between warfarin and edoxaban 60 mg with a score of 3 (interquartile range [IQR] 2-4). In the inverse probability of treatment-weighted pseudo-population, the thromboembolic event rate for edoxaban 60 mg was 0.95 and 1.0 for warfarin, corresponding weighted HR of 1.00 (95% confidence intervals [CI] 0.59, 1.71). Edoxaban 60 mg users were associated with lower rates of all-cause mortality (3.93) compared to warfarin (6.04), with a HR of 0.64 (95% CI 0.47 to 0.88). The event rates for bleeding were 3.36 and 3.14, respectively; HR 1.09 (95% CI 0.77, 1.57) Conclusion: Edoxaban 60 mg is a safe and effective treatment compared with warfarin for stroke prevention in routine clinical care for white European patients with AF, with non-significantly different risks for stroke and clinically relevant bleeding, but lower all-cause mortality. 



2014 ◽  
Vol 34 (1) ◽  
pp. 106-117 ◽  
Author(s):  
Susan Gruber ◽  
Roger W. Logan ◽  
Inmaculada Jarrín ◽  
Susana Monge ◽  
Miguel A. Hernán


2016 ◽  
Vol 25 (6) ◽  
pp. 2750-2766 ◽  
Author(s):  
Hélène Jacqmin-Gadda ◽  
Paul Blanche ◽  
Emilie Chary ◽  
Célia Touraine ◽  
Jean-François Dartigues

Semicompeting risks and interval censoring are frequent in medical studies, for instance when a disease may be diagnosed only at times of visit and disease onset is in competition with death. To evaluate the ability of markers to predict disease onset in this context, estimators of discrimination measures must account for these two issues. In recent years, methods for estimating the time-dependent receiver operating characteristic curve and the associated area under the ROC curve have been extended to account for right censored data and competing risks. In this paper, we show how an approximation allows to use the inverse probability of censoring weighting estimator for semicompeting events with interval censored data. Then, using an illness-death model, we propose two model-based estimators allowing to rigorously handle these issues. The first estimator is fully model based whereas the second one only uses the model to impute missing observations due to censoring. A simulation study shows that the bias for inverse probability of censoring weighting remains modest and may be less than the one of the two parametric estimators when the model is misspecified. We finally recommend the nonparametric inverse probability of censoring weighting estimator as main analysis and the imputation estimator based on the illness-death model as sensitivity analysis.



Sign in / Sign up

Export Citation Format

Share Document